Literature DB >> 11120998

Use of a recombinant strain of Mycobacterium avium expressing beta-galactosidase to evaluate the activities of antimycobacterial agents inside macrophages.

G Maisetta1, G Batoni, M Pardini, A Boschi, D Bottai, S Esin, M Campa, S Senesi.   

Abstract

A reliable and low-cost method that enables rapid screening of the activity exerted by new antimicrobial agents on intracellularly growing Mycobacterium avium has been developed. To this aim, a recombinant (lacZ) strain of M. avium expressing the Escherichia coli beta-galactosidase gene was used to evaluate, in murine macrophages, the susceptibility of M. avium to common antimycobacterial agents. beta-Galactosidase levels, measured in the presence of each of the antibiotics tested, were closely correlated with the number of CFU recovered from the M. avium lacZ strain-infected macrophages.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120998      PMCID: PMC90293          DOI: 10.1128/AAC.45.1.356-358.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Localized Mycobacterium avium intracellulare psoas abscess in patients with AIDS after antiretroviral therapy.

Authors:  A E Boyd; R P Brettle
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

2.  Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.

Authors:  P P Sendi; B A Craig; G Meier; D Pfluger; A Gafni; M Opravil; M Battegay; H C Bucher
Journal:  J Antimicrob Chemother       Date:  1999-12       Impact factor: 5.790

3.  Reporter gene technology to assess activity of antimycobacterial agents in macrophages.

Authors:  T M Arain; A E Resconi; D C Singh; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 4.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

5.  Intraphagocytic penetration of antibiotics.

Authors:  P Van der Auwera; T Matsumoto; M Husson
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

6.  Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans?

Authors:  J P Sison; Y Yao; C A Kemper; J R Hamilton; E Brummer; D A Stevens; S C Deresinski
Journal:  J Infect Dis       Date:  1996-03       Impact factor: 5.226

Review 7.  Cell envelope constituents and the multifaceted nature of Mycobacterium avium pathogenicity and drug resistance.

Authors:  N Rastogi; W W Barrow
Journal:  Res Microbiol       Date:  1994 Mar-Apr       Impact factor: 3.992

8.  A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase.

Authors:  R C Cooksey; J T Crawford; W R Jacobs; T M Shinnick
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

9.  Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents.

Authors:  D M Yajko; P S Nassos; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

10.  Analysis of the Mycobacterium bovis hsp60 promoter activity in recombinant Mycobacterium avium.

Authors:  G Batoni; G Maisetta; W Florio; G Freer; M Campa; S Senesi
Journal:  FEMS Microbiol Lett       Date:  1998-12-01       Impact factor: 2.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.